Loading organizations...
Key people at 3SBio.
3SBio was founded in 1993 by Dr. Jing Lou (Chairman of the board of directors and Chief Executive Officer, Director /Founder).
3SBio operates as a biopharmaceutical enterprise, integrating research, development, manufacturing, and commercialization of innovative biologics. It focuses on recombinant protein products and antibody drugs, leveraging advanced mammalian cell technology. Core therapeutic offerings, such as EPIAO and TPIAO, address significant unmet medical needs across therapeutic areas, providing comprehensive biopharmaceutical solutions.
Established in 1993 as Shenyang Sunshine Pharmaceuticals Co., Ltd., 3SBio was founded by Major General Lou Dan. His insight addressed the escalating demand for advanced therapeutic options in China, emphasizing recombinant protein medicines. This strategic focus positioned the company as a significant developer of novel biological treatments within the biopharmaceutical sector.
3SBio primarily serves a broad patient population, especially within the Chinese market, delivering essential and innovative biopharmaceutical products. Its vision prioritizes advancing global health through continuous innovation in drug discovery. The company aims to broaden its portfolio of high-quality biologics, dedicated to enhancing patient well-being and contributing to medical progress.
3SBio was founded in 1993 by Dr. Jing Lou (Chairman of the board of directors and Chief Executive Officer, Director /Founder).
Key people at 3SBio.
3SBio has 1 tracked investment across 1 company. The latest tracked deal is $50.0M Series B in Allorion Therapeutics in March 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2023 | Allorion Therapeutics | $50.0M Series B | INCE Capital, Chen KAN | Amino Capital, SUE XU, LongRiver Investments, Octagon Capital, WEI Cheng |
